455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Director Election Results at Nektar Therapeutics Annual Meeting
Nektar Therapeutics Enters $150 Million Equity Distribution Agreement
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Announces Pricing of Upsized $325 Million Public Offering
Reg. FD, Other Events
Nektar Therapeutics Reports $741.7 Million in Cash and Investments
Reports Fourth Quarter and Full Year 2025 Financial Results
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership